OncoMatch/Clinical Trials/NCT07702162
A Clinical Study of PA5 in Patients With Advanced Solid Tumors
Is NCT07702162 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies PA5 for advanced solid tumors.
Treatment: PA5 — The goal of this clinical trial is to learn if PA5 is safe and works to treat advanced solid tumors in adults. It will also learn about the tolerability and PK/PD profile of PA5. The main questions it aims to answer are: * Is intravenous infusion of PA5 monotherapy safe and tolerable for patients with advanced/metastatic solid tumors? * What is the maximum tolerated dose (MTD) and recommended dose for Phase II clinical trials (RP2D) of PA5 monotherapy? In the escalation phase, participants will receive PA5 via intravenous infusion on Day 1 of Cycle 1 (28-day cycle). If no dose-limiting toxicity (DLT) occurs, treatment continues from Cycle 2 onward with adjusted frequency (every 2-4 weeks). In the expansion phase, participants will receive PA5 with the frequency determined based on the results of the escalation phase.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: ADI-PEG20 or other drugs of the same class (ADI-PEG20)
Prior treatment with ADI-PEG20 or other drugs of the same class
Lab requirements
Blood counts
adequate organ and bone marrow function
Kidney function
adequate organ and bone marrow function
Liver function
adequate organ and bone marrow function
Participants must have adequate organ and bone marrow function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07702162 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior ADI-PEG20 or other drugs of the same class disqualifies patients from enrollment.
What disease stage is eligible?
Stage III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify